Shelton-based NanoViricides reports it has signed a licensing agreement with Karveer Meditech of Kolhapur, India. The agreement will allow Karveer to commercialize NanoViricides’ COVID drugs NV-CoV-2 and NV-CoV-2-R.
NV-CoV-2 is referred to as a “re-infection blocker” by the company. The drug is designed to directly attack the COVID virus and disable it.